Nine-count complaint alleges fraud, false advertising, breach of contract, and patent infringement
WESTMINSTER, CA / ACCESS Newswire / November 12, 2025 / BioLargo, Inc. (OTCQX:BLGO), a cleantech innovator that develops and commercializes sustainable technologies, announced today that it has filed a lawsuit in the U.S. District Court for the Central District of California to protect its patented CupriDyne odor control technology and its related products, that built the Pooph pet-products brand.
The suit (United States District Court, Central District of California, case number 8:25-cv-02516) names Pooph Inc., a Nevada corporation, and Ikigai Marketing Works LLC, a Nevada limited liability company, as defendants, alleging patent infringement (35 U.S.C. 271), false advertising (15 U.S.C. 1125), and state law claims including breach of contract, false promise, unfair and fraudulent business practices, and constructive fraud. In the suit, BioLargo seeks (i) an order that the defendants have infringed on its patents, an injunction enjoining defendants from further infringing on its patents, and accounting for defendants' gains and profits; (ii) an order that defendants have violated Section 43(a) of the Lanham Act, an injunction preventing defendants from using product reviews based on BioLargo's proprietary technology with their newly formulated products, and an accounting and damages for these violations; (iii) compensatory damages for unpaid royalties of $1,667,292; (iv) compensatory damages for unpaid product purchased from ONM Environmental of $2,154,110, (v) compensatory damages in an amount according to proof for false promises and unfair and fraudulent business practices; (vi) treble and/or exemplary damages; and (vii) costs and attorneys' fees.
"Our patented technology is the foundation that made Pooph successful," said Dennis P. Calvert, President and CEO of BioLargo. "When the licensee failed to meet its financial obligations and acted outside the contract, we revoked the license and moved to protect our rights."
BioLargo emphasized that the dispute is limited to the Pooph license and is not expected to materially affect the company's other business units or growth initiatives. The company remains financially stable and continues to expand its technology portfolio across consumer, industrial, and environmental markets, including healthcare.
BioLargo emphasizes that its focus now is on protecting its intellectual property and redeploying its technology with new partners that share its commitment to quality, transparency, and integrity.
About BioLargo, Inc.
BioLargo, Inc. (OTCQX:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.
Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863
Safe Harbor Act
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.
SOURCE: BioLargo, Inc
View the original press release on ACCESS Newswire